Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.45 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8101163 | 0.80 | CACNA1B (0.51) | ALDH1A1MAPK1HIF1AMEN1POLB | |
| SCHEMBL14117645 | 0.79 | ALDH1A1 (0.66) | RAB9ANPC1LMNAALDH1A1SLC22A2 | |
| SCHEMBL853579 | 0.78 | MLYCD (0.59) | RAB9ANPC1LMNAALDH1A1CYP2C19 | |
| SCHEMBL8587216 | 0.77 | NPC1 (0.57) | RAB9ANPC1LMNAALDH1A1SLC22A2 | |
| SCHEMBL26661489 | 0.77 | ALDH1A1 (0.71) | RAB9ANPC1LMNAALDH1A1MEN1 | |
| SCHEMBL10703559 | 0.76 | LMNA (0.44) | RAB9ANPC1LMNAALDH1A1SLC22A2 | |
| SCHEMBL12460109 | 0.76 | RAB9A (0.65) | RAB9ANPC1LMNAALDH1A1SLC22A2 | |
| SCHEMBL5940593 | 0.75 | NPC1 (0.55) | RAB9ANPC1LMNAALDH1A1SLC22A2 | |
| SCHEMBL11217430 | 0.75 | NPC1 (0.51) | RAB9ANPC1LMNAKDM4EMAPT | |
| SCHEMBL854839 | 0.74 | MAPT (0.63) | RAB9ANPC1LMNAALDH1A1SLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858399-B2 | Synthesis and application of procainamide analogs for use in an immunoassay | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080039656-A1 | Synthesis and Application of Procainamide Analogs for Use in an Immunoassay | DADE BEHRING INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-7279340-B2 | Synthesis and application of procainamide analogs for use in an immunoassay | DADE BEHRING INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20050227288-A1 | Synthesis and application of procainamide analogs for use in an immunoassay | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039656-A1 | Synthesis and Application of Procainamide Analogs for Use in an Immunoassay | CPA3, CMA1, PAFAH1B3 | RAB9A 4711/4885NPC1 4348/4885LMNA 468/4885 |
| US-20050227288-A1 | Synthesis and application of procainamide analogs for use in an immunoassay | CPA3, CMA1, PAFAH1B3 | RAB9A 4711/4885NPC1 4348/4885LMNA 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.